High density lipoprotein and coronary heart disease: Insights from mutations leading to low high density lipoprotein

Current Opinion in Lipidology

Volumn 8, Issue 4, 1997, Pages 219-224

  Calabresi, Laura ^a   Franceschini, Guido ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; HYPOLIPOPROTEINEMIA; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN DEFICIENCY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TANGIER DISEASE;

APOLIPOPROTEIN A-I; CORONARY DISEASE; HUMANS; LIPOPROTEIN LIPASE; LIPOPROTEINS, HDL; MUTATION; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; TANGIER DISEASE;

EID: 0030878533     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199708000-00005     Document Type: Review

References (46)

1. Goldbourt U, Yaari S, Medalie JH: Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997, 17:107 113.
2. Hausmann D, Johnson JA, Sudhir K, Mullen WL, Friedrich G, Fitzgerald PJ, Chou TM, Ports TA, Kane JP, Malloy MJ, Yock PG: Angiographically silent atherosclerosis detected by intravascular ultrasound in patients with familial hypercholesterolemia and familial combined hyperlipidemia: correlation with high density lipoproteins. J Am Coll Cardiol 1996, 27:1562 1570. The extent of atherosclerosis in coronary and iliac arteries was investigated in 48 asymptomatic hyperlipidemic patients, using intravascular ultrasound imaging. The authors concluded that intravascular ultrasound detects plaque more frequently than angiography; by stepwise multiple regression analysis, the strongest predictors for plaque extent and severity were plasma HDL-cholesterol and total/HDL-cholesterol ratio.
3. Barter PJ, Rye KA: High density lipoproteins and coronary heart disease. Atherosclerosis 1996, 121:1 12.
4. Schultz JR, Rudin EM: The properties of HDL in genetically engineered mice. Curr Opin Lipidol 1994, 5:126 137.
5. Duverger N, Viglietta C, Berthou L, Emmanuel F, Tailleux A, Parmentier-Nihoul L, Laine B, Fievet C, Castro G, Fruchart JC et al.: Transgenic rabbits expressing human apolipoprotein A-I in the liver. Arterioscler Thromb Vasc Biol 1996, 16:1424-142.
6. Duverger N, Kruth H, Emmanuel F, Caillaud JM, Viglietta C, Castro GR, Tailleux A, Fievet C, Fruchart JC, Houdebine LM et al.: Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation 1996, 94:713 717. In this study the authors demonstrate that the overexpression of human apoA-I in rabbits enhances plasma HDL levels and protects the aorta from diet-induced atherosclerosis.
7. Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard PM, Dagenais GR, Despres JP: Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation 1996, 94:273-278.
8. Zhong S, Sharp DS, Grove JS, Bruce C, Yano K, Curb JD, Tall AR: Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996, 97:2917 2923. A large cross-sectional examination of the relationship between mutations in the cholesteryl ester transfer protein gene and CDH.
9. Fielding CJ, Havel RJ: Cholesteryl ester transfer protein: friend or foe? J Clin Invest 1996, 97:2687 2688.
10. Brand K, Dugi KA, Brunzell JD, Nevin DN, Santamarina-Fojo S: A novel A→G mutation in intron 1 of the hepatic lipase gene leads to alternative splicing resulting in enzyme deficiency. J Lipid Res 1996, 37:1213 1223.
11. Franceschini G: Apolipoprotein function in health and disease. Insights from natural mutations. Eur J Clin Invest 1996, 26:733 746. A recent review examining the effect of natural apolipoprotein mutants on lipoprotein metabolism and cardiovascular risk.
12. Moriyama K, Sasaki J, Takada Y, Matsunaga A, Fukui J, Albers JJ, Arakawa K: A cysteine-containing truncated apoA-I variant associated with HDL deficiency. Arterioscler Thromb Vasc Biol 1996, 16:1416 1423. The authors describe a novel mutation in the apoA-I gene identified in a Japanese woman with HDL deficiency, xanthomas, corneal opacities and partial LCAT and cholesteryl ester transfer protein deficiency, but no evidence of CHD.
13. Holvoet P, Zhao Z, Deridder E, Dhoest A, Collen D: Effects of deletion of the carboxyl-terminal domain of ApoA-I or of its substitution with helices of ApoA-II on in vitro and in vivo lipoprotein association. J Biol Chem 1996, 271:19395 19401.
14. Miccoli R, Bertolotto A, Navalesi R, Odoguardi L, Boni A, Wessling J, Funke H, Wiebusch H, Eckardstein A, Assmann G: Compound heterozygosity for a structural apolipoprotein A-I variant, apoA-I(L141R)Pisa, and an apolipoprotein A-I null allele in patients with absence of HDL cholesterol, corneal opacifications, and coronary heart disease. Circulation 1996, 94:1622 1628. The paper describes an Italian family with HDL deficiency caused by compound heterozygosity for a nucleotide deletion and a missense mutation in the apoA-I gene, and premature atherosclerosis.
15. Palgunachari MN, Mishra VK, Lund Katz S, Phillips MC, Adeyeye SO, Alluri S, Anantharamaiah GM, Segrest JP: Only the two end helixes of eight tandem amphipathic helical domains of human apoA-I have significant lipid affinity. Implications for HDL assembly. Arterioscler Thromb Vasc Biol 1996, 16:328 338.
16. Fln. Dominantly inherited hypoalphalipoproteinemia due to a single base substitution in the apolipoprotein A-I gene. Arterioscler Thromb Vasc Biol 1997, 17:83 90.
17. Milano mutant, in which the same substitution occurs at residue 173.
18. Moriyama K, Sasaki J, Matsunaga A, Takada Y, Kagimoto M, Arakawa K: Identification of two apolipoprotein variants, A-I Karatsu (Tyr 100→His) and A-I Kurume (His 162→GIn). Clin Genet 1996, 49:79-84.
19. Fin mutation (Leu159-Arg) and low HDL cholesterol level without coronary artery disease. Atherosclerosis 1996, 127:239 243.
20. Booth DR, Tan SY, Booth SE, Tennent GA, Hutchinson WL, Hsuan JJ, Totty NF, Truong O, Soutar AK, Hawkins PN et al.: Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene. J Clin Invest 1996, 97:2714 2721. A novel amyloidogenic variant of apoA-I was identified in a Spanish family with autosomal-dominant nonneurophatic hereditary amyloidosis.
21. Owen JS, Wiebusch H, Cullen P, Watts GF, Lima VL, Funke H, Assmann G: Complete deficiency of plasma lecithin-cholesterol acyltransferase (LCAT) activity due to a novel homozygous mutation (Gly-30-Ser) in the LCAT gene. Hum Mutat 1996, 8:79-82.
22. Contacos C, Sullivan DR, Rye KA, Funke H, Assmann G: A new molecular defect in the lecithin: cholesterol acyltransferase (LCAT) gene associated with fish eye disease. J Lipid Res 1996, 37:35-44.
23. Kuivenhoven JA, Weibusch H, Pritchard PH, Funke H, Benne R, Assmann G, Kastelein JJ: An intronic mutation in a lariat branchpoint sequence is a direct cause of an inherited human disorder (fish-eye disease). J Clin Invest 1996, 98:358 364.
24. Kuivenhoven JA, Stalenhoef AF, Hill JS, Demacker PN, Errami A, Kastelein JJ, Pritchard PH: Two novel molecular defects in the LCAT gene are associated with fish eye disease. Arterioscler Thromb Vasc Biol 1996, 16:294 303. An interesting study describing a new case of FED caused by compound heterozygosity for two different mutations in the LCAT gene, associated with premature coronary artery disease. A review of clinical data on previously published cases of partial LCAT deficiency raises questions on the risk of atherosclerosis in this syndrome.
25. Hoeg JM, Vaisman BL, Demosky SJ Jr, Meyn SM, Talley GD, Hoyt RF Jr, Feldman S, Berard AM, Sakai N, Wood D et al.: Lecithin:cholesterol acyltransferase overexpression generates hyperalphalipoproteinemia and a nonatherogenic lipoprotein pattern in transgenic rabbits. J Biol Chem 1996, 271:4396-4402.
26. Hoeg JM, Santamarina-Fojo S, Berard AM, Cornhill JF, Herderick EE, Feldman SH, Haudenschild CC, Vaisman BL, Hoyt RF Jr, Demosky SJ Jr, et al.: Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc Natl Acad Sci USA 1996, 93:11448 11453.
27. Seguret-Mace S, Latta-Mahieu M, Castro G, Luc G, Fruchart JC, Rubin E, Denefle P, Duverger N: Potential gene therapy for lecithin-cholesterol acyltransferase (LCAT)-deficient and hypoalphalipoproteinemic patients with adenovirus-mediated transfer of human LCAT gene. Circulation 1996, 94:2177 2184. A gene therapy approach to prevent atherosclerosis in hypoalphalipoproteinemia.
28. Murthy V, Julien P, Gagne C: Molecular pathobiology of the human lipoproteln lipase gene. Pharmacol Ther 1996, 70:101 135.
29. Rouis M, Lohse P, Dugi KA, Beg OU, Ronan R, Talley GD, Brunzell JD, Santamarina-Fojo S: Homozygosity for two point mutations in the lipoprotein lipase (LPL) gene in a patient with familial LPL deficiency: LPL(Asp9→Asn, Tyr262→His). J Lipid Res 1996, 37:651 661.
30. Benlian P, de Gennes JL, Foubert L, Zhang H, Gagne SE, Hayden MR: Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med 1996, 335:848-854. The association of premature atherosclerosis with LPL deficiency is still controversial. This study describes four patients with chylomicronemia caused by mutations in the LPL gene who developed atherosclerosis before the age of 55 years.
31. Bijvoet S, Gagne SE, Moorjani S, Gagne C, Henderson HE, Fruchart JC, Dallongeville J, Alaupovic P, Prins M, Kastelein JJ, Hayden MR: Alterations in plasma lipoproteins and apolipoprotelns before the age of 40 in heterozygotes for lipoprotein lipase deficiency. J Lipid Res 1996, 37:640 650. The lipid/lipoprotein profile in a single large French-Canadian family with the P207L mutation in the LPL gene. The study shows significant disturbances in lipoprotein metabolism in heterozygote carriers, clearly supporting the key role of LPL in determining the lipid composition of lipoproteins. Alterations are sometimes evident before the age of 20 years and would predict an increased susceptibility to atherosclerosis.
32. Bagdade JD, Ritter MC, Lithell H, Bassett D, Mailly F, Talmud P, Hayden MR: Reduced cholesteryl ester transfer in plasma of patients with lipoprotein lipase deficiency. J Lipid Res 1996, 37:1696 1703.
33. Zhang H, Henderson H, Gagne SE, Clee SM, Miao L, Liu G, Hayden MR: Common sequence variants of lipoproteln lipase: standardized studies of in vitro expression and catalytic function. Biochim Biophys Acta 1996, 1302:159 166.
34. Pimstone SN, Clee SM, Gagne SE, Miao L, Zhang H, Stein EA, Hayden MR: A frequently occurring mutation in the lipoprotein lipase gene (Asn291Ser) results in altered postprandial chylomicron triglyceride and retinyl palmitate response in normolipidemic carriers. J Lipid Res 1996, 37:1675 1684.
35. Mailly F, Fisher RM, Nicaud V, Luong LA, Evans AE, Marques Vidai P, Luc G, Arveiler D, Bard JM, Poirier O et al.: Association between the LPL-D9N mutation in the lipoprotein lipase gene and plasma lipid traits in myocardial infarction survivors from the ECTIM Study. Atherosclerosis 1996, 122:21 28.
36. Hoffer MJ, Bredie SJ, Boomsma DI, Reymer PW, Kastelein JJ, de Knijff P, Demacker PN, Stalenhoef AF, Havekes LM, Frants RR: The lipoprotein lipase (Asn291→Ser) mutation is associated with elevated lipid levels in familial with familial combined hyperlipidaemia. Atherosclerosis 1996, 119:159 167.
37. Yang WS, Nevin DN, Iwasaki L, Peng R, Brown BG, Brunzell JD, Deeb SS: Regulatory mutations in the human lipoprotein lipase gene in patients with familial combined hyperlipidemia and coronary artery disease. J Lipid Res 1996, 37:2627 2637
38. de Bruin TW, Mailly F, van Barlingen HH, Fisher R, Castro Cabezas M, Talmud P, Dallinga-Thie GM, Humphries SE: Lipoprotein lipase gene mutations D9N and N291S in four pedigrees with familial combined hyperlipidaemia. Eur J Clin Invest 1996, 26:631 639.
39. Jukema JW, van Boven AJ, Groenemeijer B, Zwinderman AH, Reiber JH, Bruschke AV, Henneman JA, Molhoek GP, Bruin T, Jansen H, Gagne E et al.: The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. Circulation 1996, 94:1913 1918. Heterozygosity for a LPL mutation in patients enrolled in the REGRESS trial causes minor changes in plasma lipids but is associated with more progression of coronary atherosclerosis.
40. Wang XL, McCredie RM, Wilcken DE: Common DNA polymorphisms at the lipoprotein lipase gene. Association with severity of coronary artery disease and diabetes. Circulation 1996, 93:1339 1345.
41. Nevin DN, Zambon A, Furlong CE, Richter RJ, Humbert R, Hokanson JE, Brunzell JD: Paraoxonase genotypes, lipoprotein lipase activity, and HDL. Arterioscler Thromb Vasc Biol 1996, 16:1243 1249.
42. Serfaty Lacrosniere C, Civeira F, Lanzberg A, Isaia P, Berg J, Janus ED, Smith MP Jr, Pritchard PH, Frohlich J, Lees RS et al.: Homozygous Tangler disease and cardiovascular disease. Atherosclerosis 1994, 107:85 98.
43. Francis GA, Knopp RH, Oram JF: Defective removal of cellular cholesterol and phospholiplds by apolipoprotein A-I in Tangier Disease. J Clin Invest 1995, 96:78-87.
44. Rogler G, Trumbach B, Klima B, Lackner KJ, Schmitz G: HDL-mediated efflux of intracellular cholesterol is impaired in fibroblasts from Tangier disease patients. Arterioscler Thromb Vasc Biol 1995, 15:683 690.
45. Drobnik W, Mollers C, Resink T, Schmitz G: Activation of phosphatidylinositol-specific phospholipase C in response to HDL3 and LDL is markedly reduced in cultured fibroblasts from Tangier patients. Arterioscler Thromb Vasc Biol 1995, 15:1369 1377.
46. Walter M, Reinecke H, Gerdes U, Noter JR, Hobbel G, Seedorf U, Assmann G: Defective regulation of phosphatidylcholine-specific phospholipases C and D in a kindred with Tangier disease. Evidence for the involvement of phosphatidylcholine breakdown in HDL-mediated cholesterol efflux mechanisms. J Clin Invest 1996, 98: 2315 2323. An in-vitro study in fibroblasts investigating signaling pathways involved in HDL-mediated mobilization of intracellular cholesterol and phospholipids, which are defective in TD.